Total Payments
$281,208
2024 Payments
$23,086
Companies
49
Transactions
2,052
Medicare Patients
19,516
Medicare Billing
$1.8M
Payment Breakdown by Category
Other$225,052 (80.0%)
Food & Beverage$36,474 (13.0%)
Travel$11,288 (4.0%)
Consulting$6,725 (2.4%)
Education$1,669 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $222,802 | 115 | 79.2% |
| Food and Beverage | $36,474 | 1,857 | 13.0% |
| Travel and Lodging | $11,288 | 29 | 4.0% |
| Consulting Fee | $6,725 | 4 | 2.4% |
| Honoraria | $2,250 | 2 | 0.8% |
| Education | $1,669 | 45 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $64,179 | 328 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $62,094 | 233 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $42,610 | 84 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $34,450 | 87 | $0 (2019) |
| Insmed, Inc. | $29,498 | 69 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $18,111 | 98 | $0 (2021) |
| Amgen Inc. | $6,755 | 39 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,149 | 181 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $3,123 | 98 | $0 (2024) |
| ANI Pharmaceuticals, Inc. | $2,869 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,086 | 222 | AstraZeneca Pharmaceuticals LP ($15,688) |
| 2023 | $22,468 | 201 | AstraZeneca Pharmaceuticals LP ($10,495) |
| 2022 | $40,415 | 254 | AstraZeneca Pharmaceuticals LP ($16,488) |
| 2021 | $42,676 | 243 | Mallinckrodt Hospital Products Inc. ($16,334) |
| 2020 | $26,141 | 214 | GlaxoSmithKline, LLC. ($14,470) |
| 2019 | $77,284 | 398 | GlaxoSmithKline, LLC. ($34,599) |
| 2018 | $21,371 | 271 | Mallinckrodt LLC ($12,088) |
| 2017 | $27,767 | 249 | Mallinckrodt LLC ($13,542) |
All Payment Transactions
2,052 individual payment records from CMS Open Payments — Page 1 of 83
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $8.12 | General |
| Category: Immunology | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: ANTIBIOTIC | ||||||
| 12/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: Immunology | ||||||
| 12/17/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $32.35 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $34.53 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $9.19 | General |
| Category: Immunology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $38.48 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $17.17 | General |
| Category: HFCWO | ||||||
| 12/06/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $7.86 | General |
| Category: HFCWO | ||||||
| 12/06/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $1.12 | General |
| Category: HFCWO | ||||||
| 12/05/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $30.21 | General |
| Category: RESPIRATORY | ||||||
| 12/02/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $31.47 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $28.58 | General |
| Category: Pulmonology | ||||||
| 11/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.98 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $9.57 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $1.53 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $0.88 | General |
| Category: Immunology | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,350.00 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 4,092 | 8,507 | $1.1M | $379,084 |
| 2022 | 21 | 4,614 | 9,279 | $1.2M | $415,438 |
| 2021 | 20 | 5,333 | 11,871 | $1.4M | $497,221 |
| 2020 | 24 | 5,477 | 13,133 | $1.6M | $463,098 |
Total Patients
19,516
Total Services
42,790
Medicare Billing
$1.8M
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 684 | 1,830 | $228,750 | $115,774 | 50.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 457 | 884 | $150,255 | $84,639 | 56.3% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 727 | 1,373 | $137,300 | $58,331 | 42.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 689 | 1,280 | $320,000 | $51,440 | 16.1% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 658 | 1,277 | $95,775 | $24,991 | 26.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 86 | 86 | $19,350 | $10,370 | 53.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 42 | 42 | $10,890 | $6,806 | 62.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 45 | $10,125 | $5,944 | 58.7% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 139 | 142 | $22,720 | $3,563 | 15.7% |
| 94070 | Test to measure lung airway sensitivity | Office | 2023 | 63 | 63 | $13,860 | $2,934 | 21.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 102 | 102 | $10,200 | $2,900 | 28.4% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 63 | 86 | $17,200 | $2,870 | 16.7% |
| 94644 | Inhalation treatment for acute airway obstruction, first hour | Office | 2023 | 43 | 48 | $3,840 | $2,158 | 56.2% |
| 94728 | Test to measure resistance of the airways and lungs to differing frequencies | Office | 2023 | 62 | 62 | $4,650 | $1,923 | 41.4% |
| 95070 | Test for allergy using drugs | Office | 2023 | 63 | 63 | $8,820 | $1,654 | 18.8% |
| 76604 | Ultrasound scan of chest | Office | 2023 | 23 | 31 | $3,720 | $1,384 | 37.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 24 | 90 | $3,600 | $798.20 | 22.2% |
| J7674 | Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg | Office | 2023 | 64 | 932 | $932.00 | $598.57 | 64.2% |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | Office | 2023 | 25 | 29 | $580.00 | $2.79 | 0.5% |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | Office | 2023 | 20 | 20 | $200.00 | $2.36 | 1.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 16 | 22 | $225.00 | $2.11 | 0.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 864 | 2,422 | $302,850 | $157,588 | 52.0% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 835 | 1,563 | $156,300 | $69,480 | 44.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 778 | 1,451 | $362,750 | $58,851 | 16.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 387 | 616 | $86,240 | $58,354 | 67.7% |
About Dr. Carlos Silva, M.D
Dr. Carlos Silva, M.D is a Pulmonary Disease healthcare provider based in Chesapeake, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457451437.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carlos Silva, M.D has received a total of $281,208 in payments from pharmaceutical and medical device companies, with $23,086 received in 2024. These payments were reported across 2,052 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($222,802).
As a Medicare-enrolled provider, Silva has provided services to 19,516 Medicare beneficiaries, totaling 42,790 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Chesapeake, VA
- Active Since 09/22/2006
- Last Updated 04/05/2023
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1457451437
Products in Payments
- ACTHAR (Biological) $77,060
- TRELEGY ELLIPTA (Drug) $49,483
- TEZSPIRE (Biological) $36,542
- Arikayce (Drug) $27,483
- BREZTRI (Drug) $19,190
- ANORO (Drug) $12,023
- UTIBRON (Drug) $9,410
- LONHALA MAGNAIR (Drug) $8,261
- BEVESPI AEROSPHERE (Drug) $4,350
- PURIFIED CORTROPHIN GEL (Drug) $3,049
- BREZTRI AEROSPHERE (Drug) $2,200
- OPSUMIT (Drug) $2,130
- ARIKAYCE (Drug) $2,015
- ORENITRAM (Drug) $1,803
- DUPIXENT (Biological) $1,683
- NUCALA (Biological) $1,643
- Xolair (Biological) $1,319
- SYMBICORT (Drug) $1,316
- STIOLTO RESPIMAT (Drug) $1,264
- FASENRA (Biological) $1,175
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Chesapeake
Manojkumar Patel, Md, MD
Pulmonary Disease — Payments: $12,628
Pulmonary Disease $12,628
Dr. Haresh Patel, M.d, M.D
Pulmonary Disease — Payments: $3,384
Pulmonary Disease $3,384
Dr. Michelle Perello, Do, DO
Pulmonary Disease — Payments: $3,348
Pulmonary Disease $3,348
Mrs. Vandana Patel, Md, MD
Pulmonary Disease — Payments: $3,037
Pulmonary Disease $3,037
Eric Freeman, Md, MD
Pulmonary Disease — Payments: $2,061
Pulmonary Disease $2,061
Leah Zuniega, Md, MD
Pulmonary Disease — Payments: $1,988
Pulmonary Disease $1,988